Duke Cancer Institute ( Site 1005)

Durham, North Carolina 27710

0 studies enrolling now · 1 studies all time

What they study most

Melanoma

Studies at this site

• Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) — Completed